Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Autologous Stem Cell Transplantation for Patients with Acute Promyelocytic Leukemia in Second Molecular Remission

FELICETTO FERRARA, OLIMPIA FINIZIO, TIZIANA IZZO, CIRA RICCARDI, CLELIA CRISCUOLO, ANTONELLA CARBONE, ERIKA BORLENGHI and GIUSEPPE ROSSI
Anticancer Research September 2010, 30 (9) 3845-3849;
FELICETTO FERRARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: felicettoferrara@katamail.com
OLIMPIA FINIZIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TIZIANA IZZO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CIRA RICCARDI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CLELIA CRISCUOLO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTONELLA CARBONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERIKA BORLENGHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIUSEPPE ROSSI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Relapse still occurs in approximately 20-30% of patients with acute promyelocytic leukemia (APL) and, after achievement of second complete remission (CR), the optimal strategy is still controversial. We describe therapeutic results from a series of 13 patients autografted in second molecular remission (MR) by a molecular negative apheresis product. In all patients, the disease was confirmed at the molecular level and all had received the GIMEMA/AIDA protocol, achieving molecular remission at the end of consolidation. Relapse was hematological in 12 cases and molecular in one. After consolidation with chemotherapy, all patients achieved MR and received a further course plus granulocyte-colony stimulating factor as mobilizing therapy. A median of 7.6×106 (range 2.7-10) CD34-positive cells/kg were collected. In all cases, molecular evaluation of the apheresis product was negative for the promyelocytic leukemia/retinoic acid receptor alpha gene. No case of transplant-related mortality was recorded. No maintenance or consolidation therapy after autologous stem cell transplantation (ASCT) was given to any patient. After a median follow-up of 25 months from ASCT, 10 patients are alive in sustained MR, while two relapsed after ASCT and died in the setting of refractory disease; one patient achieved a third CR and is waiting for allogeneic SCT. These results suggest that ASCT performed with a molecularly negative graft in APL patients in second MR offers a valid chance for achieving a cure. Such an approach should also be considered in relapsed patients with an HLA-compatible donor, namely in those with a first CR lasting more than one year or in unfit or elderly individuals.

  • Acute promyelocytic leukemia
  • autologous transplantation
  • molecular remission

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) with peculiar morphological, cytogenetic and bio-molecular characteristics (1). Cytogenetically, APL is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, i.e. t(15;17)(q22;q21), which results in the fusion between the promyelocytic leukemia (PML) gene and retinoic acid receptor (RARa) gene (2). Because the efficacy of differentiation treatment based on retinoids and/or arsenic derivatives is strictly dependent on the presence of the PML-RARa fusion gene in leukemia cells, genetic confirmation of this specific lesion is mandatory in all cases (3). In addition, the hybrid gene is extremely important for the monitoring of therapeutic results, APL being the only AML subtype in which molecular remission (MR), defined by the absence of the leukemic transcript, represents the best indicator of therapeutic efficacy (4).

The treatment of APL represents a paradigm of therapeutic success in clinical hematology, in that more than 90% of patients achieve complete remission with over 70% cure rate (5). Notwithstanding, there are still a number of issues that are open for investigation, including reduction of early hemorrhagic death, minimization and eventually elimination of chemotherapy in low intermediate risk patients and optimal management of relapse, which still account for 5-30% of cases (6-8). Relapse is almost exclusively limited to patients with high-risk disease at presentation and approximately 3%-5% of APL patients develop extramedullary relapse, involving in most cases the central nervous system, but also other sites (9, 10). Finally, a small group of patients (<3%) experience isolated molecular relapse. While there is general agreement on the role of arsenic trioxide (ATO) as treatment of choice in first relapse (11,12), the role of hematopoietic stem cell transplantation after second CR achievement is still the object of controversy (13). Retrospective data analysis of adult patients who had relapsed and were reinduced with all-trans retinoic acid -(ATRA) and/or arsenic trioxide (ATO)-based regimen suggest that in individuals who achieve MR, autologous stem cell transplantation (ASCT) is an effective mode of consolidation therapy, with an event-free survival (EFS) >60% (14-16). In contrast, allogeneic SCT is associated with high treatment-related mortality (TRM) and generally should be reserved for individuals who fail to achieve MR at the end of consolidation therapy and, possibly, those with a very short duration of first CR (17, 18). Although good results have been achieved using SCT, the role of transplant is uncertain, since it is possible that long-term remissions can also be achieved with multiple courses of ATO and/or gemtuzumab ozogamicin (19-22). However, the superiority of ASCT vs. consolidation with further ATO courses was confirmed in a recent study on a series including 37 patients with relapsed APL (23). In this study, we describe the clinical characteristics and treatment results from a series of 13 consecutive APL patients autografted in second MR by a molecular negative apheresis product. All patients had relapsed after initial treatment including ATRA and chemotherapy.

Patients and Methods

All 13 patients with APL autografted in first relapse after initial treatment with a conventional ATRA-chemotherapy based regimen (AIDA) between January 2003 and December 2007 were included in this analysis. The median age of patients was 39 (range 18-69) years, 7 patients were male. All patients had received as induction the GIMEMA/AIDA protocol, for which details have been previously described (24). At diagnosis, according to the classification criteria of Sanz et al. (25), 2 patients were classified as being at low risk, 5 as at intermediate risk and 7 as at high risk. Morphologically, 8 patients had classical APL, while 5 were diagnosed as APL variant (M3v). One patient developed APL after treatment of multiple sclerosis with mitoxantrone. Ten patients were treated in hematological relapse, three in molecular relapse defined as two consecutive positive RT-PCRs obtained 1 month apart in patients achieving MR (3). The t(15;17(q22;q21) translocation was found in 11/11 evaluable patients, as a unique chromosomal abnormality in 10, with additional chromosomal abnormalities in one). Two patients, in whom cytogenetic analysis was unsuccessful, had molecular positivity for PML–RARa gene. At the molecular level, 9 patients showed positivity for BCR1 and 4 for BCR3. In all patients, immunophenotypic analysis, performed as previously described (26), confirmed the diagnosis of APL. At the end of consolidation, performed according to the GIMEMA/AIDA protocol, all patients had achieved hematological and MR. The median duration of first CR was of 18 (range 5-38) months; 7 patients relapsed after more than 12 months from CR1 achievement, 6 after less than 12 months. In all patients red cell concentrates were given to maintain the Hb level >8 g/dl, while platelet concentrates were administered to keep a platelet value >20×109/l. Disease-free survival (DFS) was defined as the time from CR achievement to relapse or death from any cause, overall survival (OS) as the time from diagnosis until death from any cause. DFS and OS were calculated by Kaplan–Meier method (27).

Results

Depending on the period of observation and the attitude of the caring institution, treatment of relapse consisted of: ATO (9 patients), ATRA (3 patients), intermediate dose cytosine-arabinoside (ARA-C) plus mitoxantrone (1 patient). After achieving hematological CR, all patients were consolidated with chemotherapy based on high-dose ARA-C, i.e. 3g/m2 every 12 h on days 1 3 5, (4 patients) or intermediate-dose ARA-C (1.5 g/m2 on days 1 to 5) plus mitoxantrone at 10 mg/mq on days 3-5 (8 patients). In all patients MR was documented. A further course of chemotherapy including intermediate-dose ARA-C plus mitoxantrone was given to all patients in order to perform additional in vivo purging of minimal residual disease, as well as to induce mobilization of peripheral blood stem cells (PBSCs). All patients did successfully mobilize PBSCs (median CD34+ cells collected: 7.6×109/l, range 2.8-37.6 109/l). In all cases, molecular evaluation of the apheresis product was negative for the PML–RARa gene. Negativity was also confirmed on bone marrow before ASCT in all patients, so that they were autografted with a molecularly negative graft in MR.

The conditioning regimen consisted of oral busulphan plus cyclophosphamide (BuCY) in 4 patients, BAVC (carmustine, amsacrine, etoposide and ARA-C) in 2 patients (28), oral Bu plus continuous infusion high-dose idarubicin in 4 patients (29) and intravenous busulphan plus high-dose idarubicin (30) in 2 patients.

The median number of CD34+ cells infused was 7.4×109/l. No acute toxicity was recorded after PBSC infusion. The median time to granulocyte recovery to >0.5×109/l and platelet recovery to >20×109/l was 12 (range 9-20) and 17 (range 9-46) days, respectively. All febrile patients received empiric broad-spectrum antibiotic therapy, while liposomal amphotericin B was administered to four patients as empiric treatment. Overall, 11 patients developed fever; in detail, there were 10 episodes of fever of unknown origin (FUO) and one bacterial sepsis; in all cases fever disappeared at the time of neutrophil recovery after broad-spectrum antibiotic therapy. No episode of grade 2 or higher extra-hematological toxicity was observed, apart from oral mucositis, which occurred in 6 patients (46%) and needed total parenteral nutrition in all cases. In all patients red cell concentrates were given to maintain the Hb level >8 g/dl, while platelet concentrates were administered to keep a platelet value >10×109/l. All transfused blood products were depleted of leukocytes to minimize the risk of transfusional graft versus host disease. The median number of packed red blood cell units and platelet units were 3 (1-4) and 2 (0-6), respectively. No maintenance or consolidation therapy after ASCT was given to any patient.

After a median follow-up of 40 months from diagnosis and 25 months from ASCT, 11 patients are alive; 10 of them are in sustained MR; one patient relapsed after ASCT, achieved a third molecular CR and is on a waiting list for allogeneic SCT from an unrelated donor. Two patients relapsed and died in the setting of progressive disease. Overall survival of the whole patient population is shown in Figure 1, and DFS from the time of ASCT is shown in Figure 2. The therapeutic results, hematopoietic recovery and supportive treatment are summarized in Table I.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Overall survival for the whole patient population.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Therapeutic results and toxicity.

Discussion

The role of SCT in APL is still matter of debate (13). However, there is general consensus that ASCT and allogeneic-SCT have no role in patients in first molecular CR (3). On the contrary, the optimal algorithm for managing patients with relapsed APL who achieve a second remission after administration of an ATO-based or alternative salvage regimens has not yet been established (31-33). Previous studies have clearly shown that long-term survival can be achieved with either autologous or allogeneic SCT, but morbidity and mortality remain substantially higher in patients receiving allogeneic-SCT. In a previous study, we demonstrated the possibility of mobilizing and collecting PML-RARa-negative PBSCs after consolidation therapy in relapsed APL patients (14). Other authors confirmed our findings, clearly showing that ASCT performed during molecular remission is a treatment option for pediatric patients with relapsed APL and may provide durable leukemia-free survival without the complications of allogeneic transplantation (34). More recently, mobilization of PML–RARa-negative PBSCs has been achieved with a combination of G-CSF and CXCR4 blockade in a relapsed APL patient pretreated with arsenic trioxide and failing to mobilize after consolidation chemotherapy (35). In the present study, we autografted a series of 13 APL patients who had relapsed after an ATRA/chemo-based regimen. In all patients, molecularly negative PBSCs were collected and reinfused after conditioning with different regimens in patients in second molecular CR. Only 3 patients relapsed after ASCT and neither median DFS nor median OS have been reached after a median follow-up of 45 months from diagnosis for surviving patients (Figures 1 and 2), suggesting a substantial chance of cure. In addition, no case of TRM occurred and non-hematological toxicity was mild, with the exception of severe oral mucositis occurring in patients conditioned with high-dose idarubicin and busulphan. In addition, in more than half of patients, the duration of second MR is longer than 24 months and in 7 of them (56%) longer than the first MR. In this series, most patients had a first CR lasting for more than one year and this may have accounted for the favorable results, given the pivotal prognostic role of the duration of the first CR in non M3 AML (36) as well as in APL (37). Furthermore, given that in all patients were in MR, we may have autografted potentially cured patients. However, while there is suggestion for long-term survival for a minority of relapsed APL patients reinduced and then treated with ATO/ATRA–based maintenance regimens, consolidation with ASCT has recently reported as being associated with a significantly superior clinical outcome (23).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Disease-free survival (DFS) from the time of autologous stem cell trasplantation (ASCT).

A potential limitation of our study lies in the relatively low number of patients analyzed in a retrospective manner at two hematological institutions. In addition, salvage treatment as well as conditioning regimens differed among patients. Notwithstanding, the final aim of salvage therapy, i.e. second MR, was reached in all patients and, in all cases, PBSCs were negative for the PML–RARa gene. Therefore, our series can be considered homogeneous, in that all patients were autografted in MR with molecularly negative graft. Furthermore, it should be considered that a prospective randomized trial aimed at comparison between ASCT- and allogeneic-SCT in patients with APL in second MR is clearly infeasible, given the low number of patients who would be eligible for the trial in contrast to the high number needed to reach statistical significance. In conclusion, these results suggest that ASCT performed with a molecularly negative graft in APL patients in second MR offers a valid chance for achieving a cure. Such an approach should be considered even in relapsed patients with an HLA-compatible donor, namely in those with a first CR lasting more than one year or in elderly individuals.

  • Received March 27, 2010.
  • Revision received July 7, 2010.
  • Accepted July 13, 2010.
  • Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Jurcic JG,
    2. Soignet SL,
    3. Maslak AP
    : Diagnosis and treatment of acute promyelocytic leukemia. Curr Oncol Rep 9: 337-344, 2007.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lo-Coco F,
    2. Ammatuna E
    : The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program, pp. 156-161, 2006.
  3. ↵
    1. Sanz MA,
    2. Grimwade D,
    3. Tallman MS,
    4. Lowenberg B,
    5. Fenaux P,
    6. Estey EH,
    7. Naoe T,
    8. Lengfelder E,
    9. Büchner T,
    10. Döhner H,
    11. Burnett AK,
    12. Lo-Coco F
    : Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113: 1875-1891, 2009.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Grimwade D,
    2. Jovanovic JV,
    3. Hills RK,
    4. Nugent EA,
    5. Patel Y,
    6. Flora R,
    7. Diverio D,
    8. Jones K,
    9. Aslett H,
    10. Batson E,
    11. Rennie K,
    12. Angell R,
    13. Clark RE,
    14. Solomon E,
    15. Lo-Coco F,
    16. Wheatley K,
    17. Burnett AK
    : Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27: 3650-3658, 2009.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Ferrara F
    : Acute promyelocytic leukemia: what are the treatment options? Expert Opin Pharmacother 11: 587-596, 2010.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sanz MA,
    2. Lo Coco F
    : Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. Haematologica 90: 840-845, 2005.
    OpenUrlAbstract/FREE Full Text
    1. Sanz MA
    : Recent advances in the treatment of APL. Clin Adv Hematol Oncol 4: 727-729, 2006.
    OpenUrlPubMed
  7. ↵
    1. Tallman MS
    : Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 20: 57-65, 2007.
    OpenUrlPubMed
  8. ↵
    1. Specchia G,
    2. Lo Coco F,
    3. Vignetti M,
    4. Avvisati G,
    5. Fazi P,
    6. Albano F,
    7. Di Raimondo F,
    8. Martino B,
    9. Ferrara F,
    10. Selleri C,
    11. Liso V,
    12. Mandelli F
    : Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 19: 4023-4028, 2001.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Chow J,
    2. Feusner J
    ; Isolated central nervous system recurrence of acute promyelocytic leukemia in children. Pediatr Blood Cancer 52: 11-13, 2009.
    OpenUrlPubMed
  10. ↵
    1. Sanz MA,
    2. Fenaux P,
    3. Lo Coco F,
    4. European APL Group of Experts
    : Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 90: 1231-1235, 2005.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Tallman MS
    : The expanding role of arsenic in acute promyelocytic leukemia. Semin Hematol 45(3 Suppl 2): S25-29, 2008.
    OpenUrlPubMed
  12. ↵
    1. Kharfan-Dabaja MA,
    2. Abou Mourad YR,
    3. Fernandez HF,
    4. Pasquini MC,
    5. Santos ES
    : Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant 13: 997-1004, 2007.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ferrara F,
    2. Palmieri S,
    3. Annunziata M,
    4. Pocali B,
    5. Viola A,
    6. Pane F
    : Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. Haematologica 89: 621-622, 2004.
    OpenUrlAbstract/FREE Full Text
    1. de Botton S,
    2. Fawaz A,
    3. Chevret S,
    4. Dombret H,
    5. Thomas X,
    6. Sanz M,
    7. Guerci A,
    8. San Miguel J,
    9. de la Serna J,
    10. Stoppa AM,
    11. Reman O,
    12. Stamatoulas A,
    13. Fey M,
    14. Cahn JY,
    15. Sotto JJ,
    16. Bourhis JH,
    17. Parry A,
    18. Chomienne C,
    19. Degos L,
    20. Fenaux P
    : Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group. J Clin Oncol 23: 120-126, 2005.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Linker CA,
    2. Owzar K,
    3. Powell B,
    4. Hurd D,
    5. Damon LE,
    6. Archer LE,
    7. Larson RA
    : Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplant 44: 353-359,2009.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Lo-Coco F,
    2. Romano A,
    3. Mengarelli A,
    4. Diverio D,
    5. Iori AP,
    6. Moleti ML,
    7. De Santis S,
    8. Cerretti R,
    9. Mandelli F,
    10. Arcese W
    : Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 17: 1930-1933, 2003.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Sanz MA,
    2. Labopin M,
    3. Gorin NC,
    4. de la Rubia J,
    5. Arcese W,
    6. Meloni G,
    7. Bacigalupo A,
    8. Alessandrino P,
    9. Carreras E,
    10. Iriondo A,
    11. Novitzky N,
    12. Jacobs P,
    13. Bandini G,
    14. Lo-Coco F,
    15. Frassoni F,
    16. Rocha V,
    17. Acute Leukemia Working Party (ALWP) of European Cooperative Group for Blood and Marrow Transplantation (EBMT)
    : Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 39: 461-469, 2007
    OpenUrlCrossRefPubMed
  17. ↵
    1. Tsimberidou AM,
    2. Giles FJ,
    3. Estey E,
    4. O'Brien S,
    5. Keating MJ,
    6. Kantarjian HM
    : The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132: 398-409, 2006.
    OpenUrlPubMed
    1. Breccia M,
    2. Cimino G,
    3. Diverio D,
    4. Gentilini F,
    5. Mandelli F,
    6. Lo Coco F
    : Sustained molecular remission after low-dose gemtuzumab–ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 92: 1273-4, 2007.
    OpenUrlAbstract/FREE Full Text
    1. Carmosino I,
    2. Latagliata R,
    3. Avvisati G,
    4. Breccia M,
    5. Finolezzi E,
    6. Lo Coco F,
    7. Petti MC
    : Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 89: 615-617, 2004.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Shigeno K,
    2. Naito K,
    3. Sahara N,
    4. Kobayashi M,
    5. Nakamura S,
    6. Fujisawa S,
    7. Shinjo K,
    8. Takeshita A,
    9. Ohno R,
    10. Ohnishi K
    : Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 82: 224-229, 2005.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Thirugnanam R,
    2. George B,
    3. Chendamarai E,
    4. Lakshmi KM,
    5. Balasubramanian P,
    6. Viswabandya A,
    7. Srivastava A,
    8. Chandy M,
    9. Mathews V
    : Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 15: 1479-1484, 2009.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Avvisati G,
    2. Lo Coco F,
    3. Diverio D,
    4. Falda M,
    5. Ferrara F,
    6. Lazzarino M,
    7. Russo D,
    8. Petti MC,
    9. Mandelli F
    : AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 88: 1390-1398, 1996
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Sanz MA,
    2. Lo Coco F,
    3. Martín G,
    4. Avvisati G,
    5. Rayón C,
    6. Barbui T,
    7. Díaz-Mediavilla J,
    8. Fioritoni G,
    9. González JD,
    10. Liso V,
    11. Esteve J,
    12. Ferrara F,
    13. Bolufer P,
    14. Bernasconi C,
    15. Gonzalez M,
    16. Rodeghiero F,
    17. Colomer D,
    18. Petti MC,
    19. Ribera JM,
    20. Mandelli F
    : Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96: 1247-1253, 2000.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Ferrara F,
    2. Morabito F,
    3. Martino B,
    4. Specchia G,
    5. Liso V,
    6. Nobile F,
    7. Boccuni P,
    8. Di Noto R,
    9. Pane F,
    10. Annunziata M,
    11. Schiavone EM,
    12. De Simone M,
    13. Guglielmi C,
    14. Del Vecchio L,
    15. Lo Coco F
    : CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 18: 1295-1300, 2000.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Kaplan EL,
    2. Meier P
    : Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
    OpenUrlCrossRef
  24. ↵
    1. Capria S,
    2. Latagliata R,
    3. Avvisati G,
    4. Breccia M,
    5. Cimino G,
    6. Diverio D,
    7. Petti MC,
    8. Meloni G
    : BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. Bone Marrow Transplant 36: 83-84, 2005.
    OpenUrlPubMed
  25. ↵
    1. Ferrara F,
    2. Mele G,
    3. Palmieri S,
    4. Pedata M,
    5. Copia C,
    6. Riccardi C,
    7. Izzo T,
    8. Criscuolo C,
    9. Musto P
    : Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. Hematol Oncol 27: 198-202, 2009.
    OpenUrlPubMed
  26. ↵
    1. Ferrara F,
    2. Palmieri S,
    3. De Simone M,
    4. Sagristani M,
    5. Viola A,
    6. Pocali B,
    7. Fasanaro A,
    8. Mele G
    : High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 128: 234-241, 2005.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Tallman MS,
    2. Altman JK
    : Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program, pp. 391-399, 2008.
    1. Dvorak CC,
    2. Agarwal R,
    3. Dahl GV,
    4. Gregory JJ,
    5. Feusner JH
    : Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant 14: 824-830, 2008.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kohno A,
    2. Morishita Y,
    3. Iida H,
    4. Yanada M,
    5. Uchida T,
    6. Hamaguchi M,
    7. Sawa M,
    8. Sugiura I,
    9. Yamamoto K,
    10. Mizuta S,
    11. Sao H,
    12. Naoe T,
    13. Miyamura K
    : Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol 87: 210-216, 2008.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Termuhlen AM,
    2. Klopfenstein K,
    3. Olshefski R,
    4. Rosselet R,
    5. Yeager ND,
    6. Soni S,
    7. Gross TG
    : Mobilization of PML–RARA negative blood stem cells and salvage with autologous peripheral blood stem cell transplantation in children with relapsed acute promyelocytic leukemia. Pediatr Blood Cancer 51: 521-524, 2008.
    OpenUrlPubMed
  30. ↵
    1. Stölzel F,
    2. Wermke M,
    3. Röllig C,
    4. Thiede C,
    5. Platzbecker U,
    6. Bornhäuser M
    : Mobilization of PML/RAR{alpha}-negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pretreated with arsenic trioxide. Haematologica 95: 171-172, 2009
    OpenUrlPubMed
  31. ↵
    1. Ferrara F,
    2. Palmieri S,
    3. Leoni F
    : Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 66: 181-93, 2008.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Estey EH
    : Treatment options for relapsed acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16: 521-34, 2003.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 30 (9)
Anticancer Research
Vol. 30, Issue 9
September 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Autologous Stem Cell Transplantation for Patients with Acute Promyelocytic Leukemia in Second Molecular Remission
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Autologous Stem Cell Transplantation for Patients with Acute Promyelocytic Leukemia in Second Molecular Remission
FELICETTO FERRARA, OLIMPIA FINIZIO, TIZIANA IZZO, CIRA RICCARDI, CLELIA CRISCUOLO, ANTONELLA CARBONE, ERIKA BORLENGHI, GIUSEPPE ROSSI
Anticancer Research Sep 2010, 30 (9) 3845-3849;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Autologous Stem Cell Transplantation for Patients with Acute Promyelocytic Leukemia in Second Molecular Remission
FELICETTO FERRARA, OLIMPIA FINIZIO, TIZIANA IZZO, CIRA RICCARDI, CLELIA CRISCUOLO, ANTONELLA CARBONE, ERIKA BORLENGHI, GIUSEPPE ROSSI
Anticancer Research Sep 2010, 30 (9) 3845-3849;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia
  • Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era
  • Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia
  • Google Scholar

More in this TOC Section

  • Four Different Artificial Intelligence Models Versus Logistic Regression to Enhance the Diagnostic Accuracy of Fecal Immunochemical Test in the Detection of Colorectal Carcinoma in a Screening Setting
  • In-hospital Outcomes Between Total Parenteral Nutrition and Enteral Feeding in Esophageal and Gastric Cancer: A Nationwide Analysis
  • Phase II Study of the Effectiveness of the Germinated Wheat-derived Rigenase Plus Polyhexanide in the Prophylaxis for Hypofractionated Radiation-induced Acute Skin Toxicity in Breast Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire